… Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Applicability … J Boudet et al. A robust computational approach is developed to screen for compatible interactions between …
… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands … are available on the SEC’s website, located at www.sec.gov . Copies of the final prospectus supplement and the …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, … editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
… AX-1412 B4GALT1 Cardiovascular disease 2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. Financial Highlights At June 30, …
… B4GALT1 for Cardiovascular diseases mid-2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
